Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) – Research analysts at HC Wainwright cut their FY2030 earnings per share (EPS) estimates for shares of Edgewise Therapeutics in a research report issued to clients and investors on Thursday, August 6th. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($2.01) per share. Get Edgewise Therapeutics alerts:Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. Edgewise Therapeutics Company Profile(Get Free Report)Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. Featured ArticlesReceive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.